Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000950170-25-085511
Filing Date
2025-06-12
Accepted
2025-06-12 16:49:47
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 22042
  Complete submission text file 0000950170-25-085511.txt   23963
Mailing Address ONE SANSOME STREET, SUITE 1650 SAN FRANCISCO CA 94104
Business Address ONE SANSOME STREET, SUITE 1650 SAN FRANCISCO CA 94104 (415) 801-8100
Versant Venture Capital VI, L.P. (Filed by) CIK: 0001687880 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address 201 LOMAS SANTA FE DRIVE, SUITE 300 SOLANA BEACH CA 92075
Business Address 201 LOMAS SANTA FE DRIVE, SUITE 300 SOLANA BEACH CA 92075 858-925-7000
LENZ Therapeutics, Inc. (Subject) CIK: 0001815776 (see all company filings)

EIN.: 844867570 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-92660 | Film No.: 251043564
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)